Ulster University professor Tara Moore has hit back at dubious claims in the BMJ regarding the alleged accuracy of the COVID-19 antibody test from the UK Rapid Test Consortrium.
Following the dubious and controversial ‘Testing for antibodies to SARS-CoV-2’ entry into the BMJ on 11 November, Moore who was involved in a 2,000 strong trial in Northern Ireland for the test looked to cast doubt on news of alleged ineffectiveness of the test.
Technical and scientific jargon aside, Moore appears to be claiming that the previous dubious entry into the BMJ is including the wrong use cases and that it is at odds of the 100% and 97.7% sensitivity found via a previous evaluation method.
Moore replied to the BMJ to highlight a range of considerations including:
“It is important to stress we do not assess AbC-19 for its utility in detecting previous infection, our target condition is presence of antibodies.”
“We welcome further clinical evaluation of AbC-19 in large cohorts of symptomatic and asymptomatic individuals alongside larger longitudinal studies assessing COVID-19 outcomes in individuals to fully validate its implementation across all intended use cases.”
“The performance metrics of AbC-19 lateral flow test was reported against these characterised samples [reference to Euroimmun ELISA, Roche and Abbott tests] in a laboratory setting as 100% specificity and 97.7% sensitivity.”
Let’s see if the Daily Mail pick up on this one!